Intracellular trafficking of silicon particles and logic-embedded vectors.
Mesoporous silicon particles show great promise for use in drug delivery and imaging applications as carriers for second-stage nanoparticles and higher order particles or therapeutics. Modulation of particle geometry, surface chemistry, and porosity allows silicon particles to be optimized for specific applications such as vascular targeting and avoidance of biological barriers commonly found between the site of drug injection and the final destination. In this study, the intracellular trafficking of unloaded carrier silicon particles and carrier particles loaded with secondary iron oxide nanoparticles was investigated. Following cellular uptake, membrane-encapsulated silicon particles migrated to the perinuclear region of the cell by a microtubule-driven mechanism. Surface charge, shape (spherical and hemispherical) and size (1.6 and 3.2 microm) of the particle did not alter the rate of migration. Maturation of the phagosome was associated with an increase in acidity and acquisition of markers of late endosomes and lysosomes. Cellular uptake of iron oxide nanoparticle-loaded silicon particles resulted in sorting of the particles and trafficking to unique destinations. The silicon carriers remained localized in phagosomes, while the second stage iron oxide nanoparticles were sorted into multi-vesicular bodies that dissociated from the phagosome into novel membrane-bound compartments. Release of iron from the cells may represent exocytosis of iron oxide nanoparticle-loaded vesicles. These results reinforce the concept of multi-functional nanocarriers, in which different particles are able to perform specific tasks, in order to deliver single- or multi-component payloads to specific sub-cellular compartments.
Ferrati
Silvia
S
University of Texas Health Science Center, Department of NanoMedicine and Biomedical Engineering, 1825 Pressler Street, Suite 537, Houston, TX 77030, USA.
Mack
Aaron
A
Chiappini
Ciro
C
Liu
Xuewu
X
Bean
Andrew J
AJ
Ferrari
Mauro
M
Serda
Rita E
RE
D002462:Cell Membrane / Q000378:metabolism; D004337:Drug Carriers / Q000737:chemistry; D042783:Endothelial Cells / Q000378:metabolism; D004730:Endothelium, Vascular / Q000166:cytology; D005290:Ferric Compounds / Q000737:chemistry; D006801:Humans; D053768:Metal Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry; D046529:Microscopy, Electron, Transmission; D008870:Microtubules / Q000378:metabolism; D010588:Phagosomes / Q000378:metabolism; D016062:Porosity; D012825:Silicon / Q000008:administration & dosage* / Q000737:chemistry; D017550:Spectroscopy, Fourier Transform Infrared
D004337:Drug Carriers; D005290:Ferric Compounds; C000499:ferric oxide; D012825:Silicon
Biomaterials. 2008 Jan;29(3):377-84
17936897
Biomaterials. 2009 May;30(13):2440-8
19215978
EMBO J. 2007 Jan 24;26(2):313-24
17245426
Nat Nanotechnol. 2008 Mar;3(3):151-7
18654487
Pharm Res. 2003 Feb;20(2):212-20
12636159
Trends Biotechnol. 2010 Apr;28(4):181-8
20079548
Int J Nanomedicine. 2006;1(2):117-28
17722528
Bioconjug Chem. 2006 Jul-Aug;17(4):943-9
16848401
Biochem J. 1998 Dec 1;336 ( Pt 2):271-82
9820800
Small. 2008 May;4(5):577-82
18383444
Nat Rev Cancer. 2005 Mar;5(3):161-71
15738981
J Am Chem Soc. 2007 Mar 21;129(11):3333-8
17319667
Biomacromolecules. 2001 Winter;2(4):1161-8
11777388
Nanoscale. 2009 Nov;1(2):250-9
20644846
Adv Drug Deliv Rev. 2006 Dec 1;58(14):1532-55
17092599
J Cell Sci. 1998 Feb;111 ( Pt 3):303-12
9427679
Curr Vasc Pharmacol. 2004 Jul;2(3):281-99
15320826
Biomaterials. 2010 Jan;31(1):173-9
19783034
J Biol Chem. 1996 Feb 16;271(7):3803-11
8631997
Mol Cell Biol. 2003 Sep;23(18):6494-506
12944476
FASEB J. 2002 Aug;16(10):1217-26
12153989
Cytometry A. 2009 Sep;75(9):752-60
19610127
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3878-82
12644705